Listed

BriaCell Therapeutics Corp.

BCTXNasdaqCIK 1610820HealthcareFiscal year ends Jul 31

Reports and events: 149 filings

Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.

What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.

BriaCell Therapeutics Corp., Reports and events
FiledFormWhat it isAccession number
2024-06-1416:05 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-24-023860
2024-05-2408:58 ETSC 13D/AOwnership report, active investor, amended0001493152-24-021272
2024-05-1716:51 ET8-K1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits0001493152-24-020460
2024-04-0216:05 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-24-012774
2024-03-1817:15 ET10-QQuarterly reportPeriod 2024-01-310001493152-24-010354
2024-01-3117:24 ET8-K5.07 Shareholder vote results0001493152-24-004525
2024-01-0916:05 ETDEF 14AProxy statementPeriod 2024-01-090001493152-24-001830
2023-12-2016:05 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001493152-23-045569
2023-12-1417:00 ET10-QQuarterly reportPeriod 2023-10-310001493152-23-044892
2023-12-1417:00 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-23-044891
2023-11-3007:00 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-23-043142
2023-11-0308:45 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-23-039228
2023-10-2517:26 ET10-KAnnual reportPeriod 2023-07-310001493152-23-038298
2023-10-2517:25 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-23-038297
2023-09-0808:49 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-23-032041
2023-09-0716:30 ET8-K5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits0001493152-23-031982
2023-08-3117:43 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001493152-23-031061
2023-08-3117:25 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001493152-23-031359
2023-08-2516:52 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001493152-23-030245
2023-08-2116:05 ET8-K5.07 Shareholder vote results; 8.01 Other events; 9.01 Financial statements and exhibits0001493152-23-029604
2023-07-2616:05 ETDEF 14AProxy statementPeriod 2023-07-260001493152-23-025573
2023-06-2709:30 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-23-022575
2023-06-1417:18 ET10-QQuarterly reportPeriod 2023-04-300001493152-23-021287
2023-05-3116:30 ET8-K1.01 Entry into a material agreement; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-23-019652
2023-05-2211:48 ET8-K3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits0001493152-23-018481
2023-05-1516:15 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001493152-23-017363
2023-04-1716:50 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-23-012566
2023-03-3017:04 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-23-009816
2023-03-1618:00 ET10-QQuarterly reportPeriod 2023-01-310001493152-23-007796
2023-02-2308:06 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-23-005827
2023-02-1516:00 ET8-K5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001493152-23-005199
2023-02-1016:30 ET8-K8.01 Other events; 9.01 Financial statements and exhibits0001493152-23-004295
2023-01-2417:17 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-23-002354
2023-01-2316:12 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-23-002198
2023-01-1809:00 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-23-001731
2023-01-1706:01 ETDEF 14AProxy statementPeriod 2023-01-170001493152-23-001505
2023-01-1011:21 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-23-001049
2022-12-1416:44 ET10-QQuarterly reportPeriod 2022-10-310001493152-22-035452
2022-12-0809:25 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-22-034831
2022-11-3016:00 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-22-034020
2022-11-1009:00 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-22-031250
2022-10-2818:00 ET10-KAnnual reportPeriod 2022-07-310001493152-22-029742
2022-10-2818:00 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits0001493152-22-029741
2022-10-2109:00 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-22-029278
2022-09-1416:05 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001493152-22-025861
2022-08-0417:10 ET8-K1.01 Entry into a material agreement; 9.01 Financial statements and exhibits0001493152-22-021361
2022-07-1807:27 ET6-KReport of a foreign private issuerPeriod 2022-07-180001493152-22-019531
2022-07-0509:05 ET6-KReport of a foreign private issuerPeriod 2022-07-050001493152-22-018457
2022-06-2916:05 ET6-KReport of a foreign private issuerPeriod 2022-06-290001493152-22-018099
2022-06-2416:05 ET6-KReport of a foreign private issuerPeriod 2022-06-240001493152-22-017706

Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.